WO2000008043A3 - Prevention et traitement de pathologie virale - Google Patents

Prevention et traitement de pathologie virale Download PDF

Info

Publication number
WO2000008043A3
WO2000008043A3 PCT/US1999/017487 US9917487W WO0008043A3 WO 2000008043 A3 WO2000008043 A3 WO 2000008043A3 US 9917487 W US9917487 W US 9917487W WO 0008043 A3 WO0008043 A3 WO 0008043A3
Authority
WO
WIPO (PCT)
Prior art keywords
frms
fusion
antibodies
present
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017487
Other languages
English (en)
Other versions
WO2000008043A9 (fr
WO2000008043A2 (fr
Inventor
Jack H Nunberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Montana Missoula
Original Assignee
University of Montana Missoula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99945011A priority Critical patent/EP1102788A4/fr
Priority to AU57715/99A priority patent/AU5771599A/en
Priority to IL14121199A priority patent/IL141211A0/xx
Priority to BR9912732-6A priority patent/BR9912732A/pt
Priority to JP2000563676A priority patent/JP2002522448A/ja
Priority to CA002338983A priority patent/CA2338983A1/fr
Application filed by University of Montana Missoula filed Critical University of Montana Missoula
Priority to KR1020017001483A priority patent/KR20010085326A/ko
Publication of WO2000008043A2 publication Critical patent/WO2000008043A2/fr
Publication of WO2000008043A3 publication Critical patent/WO2000008043A3/fr
Anticipated expiration legal-status Critical
Publication of WO2000008043A9 publication Critical patent/WO2000008043A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la génération de structures FRMS (Fusion-Related Molecular Structures) comprenant un ou plusieurs déterminants transitionnels concernés par la fusion. On peut construire des vaccins très efficaces et qui présentent les déterminants concernés par les fusions au système immunitaire qui engendre des anticorps uniques capables de neutraliser puissamment une large gamme d'isolats primaires, et ce, avec malgré des provenances mondiales même à partir de différentes clades virales phylogénétiques. L'invention concerne des procédés permettant de former, d'isoler et de purifier la FRMS ainsi que l'utilisation de telles FRMS dans une variété de compositions et procédés, et notamment comme immunogènes vaccinaux, comme agents diagnostics et comme agents thérapeutiques. L'invention concerne notamment des FRMS capables de mettre en évidence la neutralisation d'anticorps face à des pathogènes viraux et des isolats primaires d'un virus. Des anticorps dirigés contre les FRMS peuvent servir à l'étude du chemin moléculaire aboutissant à la fusion du virus avec la cellule hôte, et à l'identification de points d'un possible blocage à médiation d'anticorps survenant sur ce chemin. L'invention concerne enfin l'utilisation d'anticorps de l'invention comme agents antiviraux, comme additifs pour produits sanguins, comme agent d'immunisation passive pour additifs contraceptifs dans le traitement postexposition ou l'immunisation foetale.
PCT/US1999/017487 1998-08-03 1999-08-03 Prevention et traitement de pathologie virale Ceased WO2000008043A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU57715/99A AU5771599A (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease
IL14121199A IL141211A0 (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease
BR9912732-6A BR9912732A (pt) 1998-08-03 1999-08-03 Estrutura molecular isolada, vìrus envelopadorecombinante, formilação de vacina, anticorpomonoclonal, anti-soro policlonal, geléia, espuma,creme ou unguento contraceptivo, amostras desangue de mamìfero e de humano, kit, linhagemcelular, processos de tratamento ou deprevenção de infecção por um vìrus em sujeito, detratamento ou de prevenção de infecção por hivem um humano, de inibição de infecção por um vìrusem uma amostra de sangue, de inibição de infecçãopor hiv em uma amostra de sangue humano, dedescontaminação de ferramentas cirúrgicas oudentais, de monitoração de produto de anticorpopara a estrutura molecular, de produção de umimunógeno para uso em uma vacina para otratamento ou a prevenção de infecção por umvìrus, e de produção de um imunólogeno para usoem uma vacina para o tratamento ou a prevençãode infecção por hiv, estrutura reticulada,anticorpo monoclonal para a estrutura, dedescontaminação de ferramentas cirúrgicas oudentais, processo de seleção de uma estruturamolecular para eficácia de vacina, mamìfero,complexo de proteìna isolado, formulação devacina, processos de imunização de um animal paraum vìrus, e de preparação de um complexo deproteìna, células fixadas, processos depurificação de um complexo de proteìna e detratamento de um hospedeiro que tem sidoexposto a um vìrus, ou de prevenção de infecçãode um hospedeiro pelo citado vìrus, e composição.
JP2000563676A JP2002522448A (ja) 1998-08-03 1999-08-03 ウイルス疾患の予防および治療
CA002338983A CA2338983A1 (fr) 1998-08-03 1999-08-03 Prevention et traitement de pathologie virale
EP99945011A EP1102788A4 (fr) 1998-08-03 1999-08-03 Prevention et traitement de pathologie virale
KR1020017001483A KR20010085326A (ko) 1998-08-03 1999-08-03 바이러스 질환의 예방과 치료

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9510598P 1998-08-03 1998-08-03
US14180699P 1999-06-29 1999-06-29
US60/141,806 1999-06-29
US60/095,105 1999-06-29

Publications (3)

Publication Number Publication Date
WO2000008043A2 WO2000008043A2 (fr) 2000-02-17
WO2000008043A3 true WO2000008043A3 (fr) 2000-05-11
WO2000008043A9 WO2000008043A9 (fr) 2001-12-13

Family

ID=26789760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017487 Ceased WO2000008043A2 (fr) 1998-08-03 1999-08-03 Prevention et traitement de pathologie virale

Country Status (9)

Country Link
EP (1) EP1102788A4 (fr)
JP (1) JP2002522448A (fr)
KR (1) KR20010085326A (fr)
CN (1) CN1321165A (fr)
AU (1) AU5771599A (fr)
BR (1) BR9912732A (fr)
CA (1) CA2338983A1 (fr)
IL (1) IL141211A0 (fr)
WO (1) WO2000008043A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
FR2789590B1 (fr) * 1999-02-15 2003-01-17 Inst Rech Developpement Ird Compositions immunogenes utilisables comme vaccins
EP1130089A1 (fr) * 2000-02-17 2001-09-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Composition comprenant des particules sous-virales cibles et fusions de virus enveloppés, et vaccin la contenant
JP2004511444A (ja) * 2000-09-22 2004-04-15 デューク・ユニバーシティー 免疫原
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
FR2819256B1 (fr) * 2001-01-05 2004-04-30 Aventis Pasteur Polypeptide induisant des anticorps neutralisant le vih
ES2260416T3 (es) * 2001-01-05 2006-11-01 Sanofi Pasteur Polipeptido que induce anticuerpos que neutralizan el vih.
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
EP1411770A4 (fr) 2001-07-05 2006-05-10 Chiron Corp Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1723178A4 (fr) 2004-03-12 2007-12-12 Human Genome Sciences Inc Recepteur humain (ccr5) hdgnr10 de chimiokine de la proteine g
GB201412494D0 (en) * 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
KR102880907B1 (ko) 2019-11-11 2025-11-04 벤더르빌트 유니버시티 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법
WO2022074180A1 (fr) * 2020-10-09 2022-04-14 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Méthode pour déterminer si des anticorps neutralisant des virus sont présents ou non et méthode in vitro de criblage de composés pour leur capacité à neutraliser un virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005147A1 (fr) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules defectives interferentes du vih avec un cd-env chimerique
US5714316A (en) * 1991-06-21 1998-02-03 The Wistar Institute Of Anatomy & Biology Chimeric envelope proteins for viral targeting

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714316A (en) * 1991-06-21 1998-02-03 The Wistar Institute Of Anatomy & Biology Chimeric envelope proteins for viral targeting
WO1993005147A1 (fr) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules defectives interferentes du vih avec un cd-env chimerique

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Also Published As

Publication number Publication date
WO2000008043A9 (fr) 2001-12-13
IL141211A0 (en) 2002-02-10
EP1102788A4 (fr) 2002-08-28
CA2338983A1 (fr) 2000-02-17
EP1102788A2 (fr) 2001-05-30
BR9912732A (pt) 2001-11-27
WO2000008043A2 (fr) 2000-02-17
AU5771599A (en) 2000-02-28
KR20010085326A (ko) 2001-09-07
CN1321165A (zh) 2001-11-07
JP2002522448A (ja) 2002-07-23

Similar Documents

Publication Publication Date Title
WO2000008043A3 (fr) Prevention et traitement de pathologie virale
Fekadu et al. Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (Eptesicus serotinus), classic rabies and rabies-related viruses
Excler et al. Prospects for a globally effective HIV-1 vaccine
WO2005116270A3 (fr) Composition de vaccin contre le virus de la grippe et ses methodes d'utilisation
BRPI0414443A (pt) imunógenos consensuais/ancestrais
EP0330359A3 (fr) Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
Xu et al. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV
Wang et al. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey
JP2008526764A5 (fr)
WO2001000232A3 (fr) Vaccin
WO2022197720A3 (fr) Compositions et méthodes de traitement d'une infection à coronavirus
DE60336978D1 (de) Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper
EP0142345A3 (fr) Vaccin anti-idiotypique à base d'anticorps monoclonaux anti-idiotypiques
Oduntan et al. The immunological response of Nigerian infants to attenuated and inactivated poliovaccines
US11780888B2 (en) Chimeric protein for coronavirus vaccine
Kempe et al. Smallpox immunization in the United States
WO2002022687A3 (fr) Proteines de fusion chimiokine virale-antigene tumoral
Farnós et al. The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice
Brydak et al. Antibody response to influenza vaccination in healthy adults
Finerty et al. Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge
EP0317622A4 (fr) Prevention et traitement de maladies retrovirales.
Vodopija et al. Rabipur: a reliable vaccine for rabies protection
Decroix et al. Mucosal Immunity Induced by Intramuscular Administration of Free Peptides In‐Line with PADRE: IgA Antibodies to the ELDKWA Epitope of HIV gp41
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
EP4265272A1 (fr) Utilisation de compositions vaccinales basées sur le domaine de liaison au récepteur du virus sars-cov-2 dans le développement d'une immunité protectrice

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99811641.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2338983

Country of ref document: CA

Ref document number: 2338983

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 141211

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001264

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017001483

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 57715/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999945011

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999945011

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017001483

Country of ref document: KR

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-92, DESCRIPTION, REPLACED BY NEW PAGES 1-92; PAGES 93-104, CLAIMS, REPLACED BY NEW PAGES 93-104; PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/23-23/23; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 1999945011

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017001483

Country of ref document: KR